Our Firm Surgo is organized as a limited partnership under the laws of the State of Delaware. Mala Gaonkar, Managing Principal and Chief Investment Officer of Surgo (“Managing Principal”), founded Surgo in 2022 and is its primary controlling limited partner. The investment activities of Surgo are led by the Managing Principal. Surgo serves as an investment manager and provides discretionary advisory services to U.S. and non-U.S. private investment funds intended for sophisticated investors and institutional investors. Surgo manages the following private, pooled investment vehicles:
• SurgoCap Master Fund LP, a Cayman Islands exempted limited partnership (“Master Fund”),
• SurgoCap Offshore Fund LP, a Cayman Islands exempted limited partnership (“Offshore Fund”), and
• SurgoCap Onshore Fund LP, a Delaware limited partnership (“Onshore Fund”). The Offshore Fund and the Onshore Fund invests all of their investable assets in the Master Fund. The Master Fund, Offshore Fund and Onshore Fund are herein each referred to as a “Fund” or collectively the “Funds”. As of March 1, 2024, Surgo had approximately $2,992,502,057 of regulatory assets under management on a discretionary basis and did not manage any client assets on a non-discretionary basis. Where appropriate, Surgo may create parallel investment vehicles, in order to facilitate investments with different tax, regulatory or other applicable circumstances, including, but not limited to, co- investments. Such other vehicles may have structures and terms that differ from those of the Funds set forth herein. Further, where a direct private investment by one of the Funds may result in adverse legal, tax, regulatory or other consequences, Surgo may establish, or cause to be established, certain alternative investment vehicles (an any related entities, as applicable) through which the Funds may participate in such investments. The term “Client” used in this Brochure refers to the Funds collectively and any other Clients managed by Surgo as of the date of this Brochure. In providing services to the Funds, Surgo formulates each Fund’s investment objectives, directs and manages the investment and reinvestment of each Fund’s assets, and provides reports to investors. Investment advice is provided directly to the Funds and not individually to the limited partners of the Funds (the “Investors” or “Limited Partners”). Surgo manages the assets of the Funds in accordance with the terms of each Fund’s confidential offering and/or private placement memoranda, individual limited partnership agreements and other governing documents applicable to each Fund (the “Governing Fund Documents”). All terms are generally established at the time of the formation of a Fund. The Investors may not restrict investments by the Funds in any capacity, and Limited Partners have limited liquidity rights

and, depending on the class, the majority of an investor’s capital may be locked up for as long as three years, as well as additional quarterly gates for withdrawal. Limited partnership interests in the Funds are not registered under the Securities Act of 1933, as amended (the “Securities Act”), and the Funds are not registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Accordingly, interests in the Funds are offered and sold exclusively to investors satisfying the applicable eligibility and suitability requirements. Surgo does not participate in any wrap fee programs. Investment Strategy The Funds’ investment objective is to provide investors with long-term capital appreciation using a "long/short" investment strategy. The Funds invest globally primarily in equity and equity-related securities of companies across the full lifecycle range where moats are widening, usually driven by the disruptive effects of technology. As a result, the Funds focus on the following broad industry categories: enterprise data, financial services, industrials, and healthcare. The Funds may make direct investments in private companies (“DIs”) and Surgo continually assesses the best risk- adjusted way to play a theme across all public and private opportunities. As part of its investment strategy, the Funds may, from time to time, invest in initial public offerings, including for purposes of reselling such securities within the first days or weeks of such initial public offering. Surgo maintains discretion to invest the assets of the Funds, directly or indirectly, in various financial instruments. Surgo performs industry-specific fundamental analysis to identify the companies it believes are best positioned for the Funds to capture value created as a result of this innovation and adaptation. On the other hand, Surgo looks to short companies in the portfolio of the Funds that are on the other side of this change. Often, this includes businesses that are being disrupted as a result of new or more effective uses of technology. Surgo may establish general risk and portfolio management targets and guidelines for each account it manages, however, Surgo reserves the right to deviate, alter, modify or invest outside the investment strategy, general guidelines and target concentration, core position ranges and relative exposure guidelines of the Funds when it deems it prudent to do so in light of available investment opportunities and/or to take advantage of changing market conditions, in each case, when Surgo concludes that alterations or modifications are consistent with the Funds' investment objectives. Such deviation or modification may be material and/or may continue for an extended period of time. The investment approach of the Funds and the guidelines set forth herein are at the discretion of Surgo and are subject to change.